Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Moderna ( (MRNA) ).
On November 20, 2025, Moderna, Inc. announced updates on its pipeline progress and business strategy during its Analyst Day. This announcement is significant as it reflects the company’s ongoing efforts to advance its mRNA technology and strengthen its position in the biotechnology sector, potentially impacting stakeholders and market dynamics.
The most recent analyst rating on (MRNA) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Moderna stock, see the MRNA Stock Forecast page.
Spark’s Take on MRNA Stock
According to Spark, TipRanks’ AI Analyst, MRNA is a Neutral.
Moderna’s overall stock score reflects significant financial challenges, including declining revenues and profitability. Technical analysis indicates weak momentum, and valuation concerns persist with a negative P/E ratio. However, strategic cost reductions and partnerships provide some optimism for future growth.
To see Spark’s full report on MRNA stock, click here.
More about Moderna
Moderna, Inc. operates in the biotechnology industry, focusing on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The company is known for its innovative approach to drug development, particularly in the field of infectious diseases, oncology, and rare diseases.
Average Trading Volume: 11,440,054
Technical Sentiment Signal: Sell
Current Market Cap: $9.45B
See more insights into MRNA stock on TipRanks’ Stock Analysis page.